Insider · CIK 0001792747
Brian T Crum
Files at LXRX (LEXICON PHARMACEUTICALS, INC.). First filing -, latest -.
In brief
Brian T Crum files SEC Form 4 as officer at LXRX (LEXICON PHARMACEUTICALS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian T Crum has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 27 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +33,457 | - | - | 363,658 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +69,386 | - | - | 330,201 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +170,163 | - | - | 533,821 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -105,019 | $1.47 | $154k | 428,802 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -69,386 | - | - | 69,387 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -33,457 | - | - | 0 | Mar 3, 2026 |
| Feb 28, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -170,163 | - | - | 340,327 | Mar 3, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +299,710 | $0.00 | $0 | 299,710 | Feb 17, 2026 |
| Feb 12, 2026 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +449,560 | $0.00 | $0 | 449,560 | Feb 17, 2026 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +26,097 | - | - | 203,594 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +33,456 | - | - | 237,050 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +69,387 | - | - | 306,437 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -45,622 | $0.67 | $31k | 260,815 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -26,097 | - | - | 0 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -33,456 | - | - | 33,457 | Mar 3, 2025 |
| Feb 28, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -69,387 | - | - | 138,773 | Mar 3, 2025 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +765,730 | $0.00 | $0 | 765,730 | Feb 18, 2025 |
| Feb 13, 2025 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +510,490 | $0.00 | $0 | 510,490 | Feb 18, 2025 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +8,750 | - | - | 143,548 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +26,096 | - | - | 169,644 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Common Stock | +33,457 | - | - | 203,101 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | FTax withholding Common Stock | -25,604 | $2.62 | $67k | 177,497 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -8,750 | - | - | 0 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -26,096 | - | - | 26,097 | Feb 29, 2024 |
| Feb 28, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | MOption exercise Restricted Stock Unitsderivative | -33,457 | - | - | 66,913 | Feb 29, 2024 |
| Feb 8, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitsderivative | +208,160 | $0.00 | $0 | 208,160 | Feb 12, 2024 |
| Feb 8, 2024 | LXRX LEXICON PHARMACEUTICALS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +208,160 | $0.00 | $0 | 208,160 | Feb 12, 2024 |
Questions about Brian T Crum
Answered from the filings on this page, as of the latest one.
Is Brian T Crum buying or selling?
Brian T Crum has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian T Crum's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian T Crum has 0.
Where does Brian T Crum file Form 4?
Brian T Crum has filed Form 4 at LXRX (LEXICON PHARMACEUTICALS, INC.) as SVP, General Counsel & Secr.. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.